cyrilzakka/clinical-trials huggingface dataset:
The Effect of tDCS Applied During Sleep on Memory Consolidation

This study will attempt to use a type of non-invasive brain stimulation technology during sleep to improve measures of sleep quality and memory in young healthy students and older adults. The type of brain stimulation is called transcranial direct current stimulation (tDCS), which uses small currents of electricity to increase or decrease the activity of specific areas of the brain.

Transcranial direct current stimulation (tDCS) is a safe, non-invasive, and inexpensive brain stimulation modality that has been shown to have the ability to modulate both cortical and deep brain structure activity. This technique has undergone a significant amount of investigation in varied neuropsychiatric populations and interest in this technique has increased dramatically as of late.

Some researchers have studied the effects of this modality on sleep as well as memory with promising results. One such study demonstrated that by using bilateral tDCS with a pattern of stimulation in the delta frequency range (0-3 Hz) delivered during slow wave sleep, that it is possible to increase delta power during slow wave sleep, as well as improve sleep efficiency. In addition to showing that it is possible to enhance slow waves, it was also demonstrated that this increase was associated with an improvement of a measure of declarative memory consolidation (one of the theorized functions of slow wave sleep). Enhancing memory function in a normal healthy group raises the possibility that it would also be possible to enhance memory in clinical populations who would benefit from such an intervention.

The investigators propose to test this intervention for replication in a similar cohort.

Eligibility Criteria:
Inclusion Criteria:

* Students
* Adults aged 60 or greater.

Exclusion Criteria:

* If they are taking any prescription or over the counter medications.
* If they have any currently active neurologic, psychiatric, hormonal, metabolic, circulatory, or sleep disturbances. -They must specifically not have a history of seizures, closed head injuries with loss of consciousness for greater than 5 minutes, any known brain tumors or lesions, metal implants or implanted devices above the neck, a history of eczema, or other sensitive conditions, or an allergy to latex.
* They must not smoke cigarettes, use illicit drugs, or meet criteria for alcohol abuse or dependence in their lifetime defined by SCID criteria.
* They must be free of alcohol for at least 48 hours prior to each night of the study
* They must not consume more than the equivalent of 500mg of caffeine daily.
Program to Overcome Pelvic Pain Study

To refine and evaluate the feasibility of procedures for a future full-scale efficacy trial of a group-based therapeutic yoga intervention versus physical conditioning (stretching and strengthening) intervention for women with chronic pelvic pain.


Eligibility Criteria:
Inclusion Criteria:

* Women aged 18 years or older who report chronic or recurrent pelvic pain for at least 6 months
* Report an average daily pain intensity score of at least 4 (on a 0 to 10 scale) on a screening 7-day pain log
* Report prior clinical evaluation of pain by a healthcare professional including at least a superficial pelvic exam
* Willing to refrain from initiating new clinical treatments that may affect their pain during the study period

Exclusion Criteria:

* Report pelvic pain occurring exclusively with menses or exclusively during sexual intercourse (note that women with at least some pain between menses or intercourse are still eligible)
* Participation in organized yoga classes or muscle strengthening programs (e.g., Pilates) in the past month, or prior yoga therapy specifically directed a pelvic pain
* Currently pregnant (by self-report or screening test), pregnant within the past 6 months, or planning pregnancy
* Diagnosed with an alternate, reversible cause of pain that is unlikely to respond to yoga and requires another treatment modality (e.g., current pelvic infection or a gynecologic dermatosis)
* Initiation, dose escalation, or weaning of pharmacologic agents that may affect pelvic pain severity in the past 1 month (e.g., pain medications, antidepressants, anticonvulsants)-note that women on stable doses will be eligible
* Surgery to the genital or pelvic structures within 3 months, or prior cancer or irradiation to these structures
* Use of formal psychological therapies specifically for pelvic pain (e.g., systematic desensitization, sex therapy, cognitive therapy, relaxation therapy) within 1 month of screening
* Use of formal behavioral therapies for pelvic or genital pain (e.g., pelvic floor rehabilitation or biofeedback performed by a certified healthcare practitioner) within 1 month of screening
* Unable to walk up a flight of stairs or at least 2 blocks on level ground (i.e., functional capacity \< 4 METs), or unable to get up from a supine to a standing position without assistance
* Participation in another interventional study that might interfere with or confound study procedures
* Known conflict with multiple available intervention class dates
* Inability to sign an informed consent or fill out questionnaires or complete study interviews in English, or lacking technical requirements to complete intervention classes or study visits by video
Radiogenomic and Prognosis Analysis in Glioma

This study aims to evaluate whether MRI can be used to predict genomics and prognosis in glioma. Given the profound prognostic significance of genetic mutations seen in glioma, there have been increasing attempts to correlate imaging characteristics with genetic, mutational and expression patterns. To be able to predict genomics and prognosis based on imaging alone will prove useful in patients with involvement of glioma in delicate areas of the brain and better reflect tumor and molecular heterogeneity.

Previous studies have proposed certain imaging characteristics correlating with genetic, molecular and expression patterns. Advanced imaging provides additional clues but no studies have examined its added value particularly in a prospective setting. The investigator's aim to evaluate preoperative MRI for patients suspected of glioma to predict IDH mutation, 1p19q codeletion, MGMT methylation and EGFR mutation status using imaging characteristics such as margin, patterns of contrast enhancement and edema as well as diffusion and perfusion characteristics. This will be confirmed pathologically and further correlated with patients' long term outcome.

Eligibility Criteria:
Inclusion Criteria:

* Patients suspected of glioma undergoing MRI examination prior to surgery
* MRI including advanced imaging such as cerebral blood volume, apparent diffusion coefficient and amide proton transfer imaging
* Signed informed consent

Exclusion Criteria:

* Pathologic confirmation as tumors other than glioma
* Patients who have any type of bioimplant activated by mechanical, electronic, or magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulates, electronic infusion pumps, etc), because such devices may be displaced or malfunction
* Patients who are pregnant or breast feeding; urine pregnancy test will be performed on women of child bearing potential
To Investigate the Prevalence of Children Asthma in China

Asthma is the most common chronic respiratory disease in children and has much effect on their life and study, which leads to huge economic burden and pressure to the whole families. Some children will develop into adult patients so that asthma can be the life-long vigorous trouble. In recent years, the prevalence rate of children asthma is increasingly going up worldwide. The prevalence rate in last 12 months reported in USA, United Kingdom, Australia, New Zealand was between 12% to 30%.

Center for Asthma Prevention and Education of Capital Institute of Pediatrics investigated the national asthma prevalence in 900 thousands children in 27 provinces and cities, which average rate was 0.11% to 2.03% in 1990. In 2000, we investigated it again in 31 provinces(43 cities) and the average national children asthma prevalence rate was 1.97%(0.25% to 4.63%) which was much higher than that in 1990.

1. Objectives

   1. To investigate the national children(0-14 years old)asthma prevalence;
   2. To compare the prevalence rate between that in 1990 and 2000;
   3. To analyse the asthma manifestations including the ages, seasons, causes, trigger and hereditary factors and their impact on the asthma patients, families and society;
   4. To identify the risk factors by questionnaires in case-control research.
2. Study Design / Clinical Plan

   1. The screening stage: to distinguish suspected asthma from the children age from 0 to 14 years old.
   2. To obtain identified asthma from the suspected asthma.
   3. To evaluate the prevalence and severe degree of 0 to 14-year-old children asthma and gain the main risk factors by case-control research.

Eligibility Criteria:
Inclusion Criteria:

* children age from 0 to 14 years

Exclusion Criteria:

* none
StEnt Coverage and Neointimal Tissue Characterization After eXtra Long evErolimus - Eluting Stent imPlantation

The objective of this study is to evaluate the rate of SYNERGY 48 mm stent strut coverage and assess neointimal progression via OCT measurement in patients who underwent PCI.

Patients with stable, unstable angina and non-ST-elevation ACS will be included in this study. Patient will undergo coronary angiography for coronary anatomy assessment and estimation indications for PCI . After screening an OCT-guided PCI with extra long SYNERGY stent implantation will be provided in all patients. Patient will be divided into 2 groups of follow-up and will be followed within 3 and 6 month after procedure. Final clinical follow-up will be assessed at 12 month for all patients. At each follow-up visits the data regarding clinical events, coronary angiography and OCT-imaging will be collected.

Eligibility Criteria:
Inclusion Criteria:

* Signed written informed consent before study procedures
* Subject is eligible for percutaneous coronary intervention (PCI)
* Left ventricular ejection fraction (LVEF) \>30%
* Reference vessel diameter (RVD) ≥2.25 mm and ≤4.0 mm
* Target lesion(s) length must be ≥38 mm
* Target lesion(s) stenosis ≥50%

Exclusion Criteria:

* History of acute or recent stroke (\<2 months)
* Contraindications for antiplatelet and/or anticoagulant therapy
* Bleeding within the last 30 days
* Subject has acute ST elevation MI (STEMI)
* Subject has cardiogenic shock, hemodynamic instability requiring inotropic or mechanical circulatory support
* Subject with out of range complete blood count (CBC) values determined as a clinically significant
* Subject has documented or suspected liver disease, including laboratory evidence of hepatitis
* Subject has baseline serum creatinine level \>2.0 mg/dL (177µmol/L)
* Subject has signs or symptoms of active heart failure (i.e., NYHA class IV) at the time of the index procedure
* Subject is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential)
* Lesion located within a saphenous vein graft or an arterial graft
* Subject has unprotected left main coronary artery disease (\>50% diameter stenosis)
* Other serious medical illness (e.g., cancer, congestive heart failure) that may reduce life expectancy to less than 12 months
Assessment of a Pre-Workout Dietary Supplement

The purpose of this study is to examine the acute effects of a pre-workout dietary supplement on energy metabolism, cardiovascular hemodynamics, blood metabolites and mental focus.

A number of nutritional strategies have been developed to optimize nutrient delivery prior to exercise. This includes providing carbohydrate and a number of ergogenic nutrients prior to, during and/or following exercise. As a result a number of pre-workout supplements have been developed to increase energy availability, promote vasodilation and/or positively affect exercise capacity. The purpose of this study is to investigate the potential ergogenic value of acute ingestion of a pre-workout dietary supplement prior to exercise.

Eligibility Criteria:
Inclusion Criteria:

* you are an apparently healthy and recreationally active man or woman between the ages of 18 and 40;
* you will need to have at least six months immediate prior history of resistance training on the bench press and leg press or squat;

Exclusion Criteria:

* you have a history of treatment for metabolic disease (i.e., diabetes), hypertension, hypo-tension, thyroid disease, arrhythmia and/or cardiovascular disease;
* you are currently using prescription medications;
* you have an intolerance to caffeine and/or other natural stimulants;
* you are pregnant or a lactating female or plan to become pregnant with the next month;
* you have a history of smoking;
* you drink excessively (i.e., 12 drinks per week or more);
Safety and Tolerability of RTX-134 in Adults With Phenylketonuria

This study will evaluate the safety and tolerability of RTX-134 in adult patients with PKU.

This is a Phase 1b first-in-human trial in adult subjects with PKU. The primary objective of this study is to evaluate the safety and tolerability of RTX-134 following intravenous administration of a single dose. RTX-134 consists of allogeneic human red cells expressing the AvPAL (Anabaena variabilis phenylalanine ammonia lyase) gene inside the cell. The trial is designed to determine a preliminary dose and inform a dosing schedule that is deemed safe, tolerable, and potentially effective. Four dose levels are planned, additional dose levels may be explored. Following administration, subjects will be monitored until 28 days after last detection of RTX-134. Detection of RTX-134 will be evaluated using multiple pharmacokinetic (PK) and pharmacodynamic (PD) assessments including measurement of trans-cinnamic acid (tCA).

Eligibility Criteria:
Inclusion Criteria

1. Age 18 years or older with:

   1. A clinical diagnosis of PKU, and
   2. Average blood phenylalanine level ≥ 600 µmol/L based on 2 assessments up to 3 weeks apart during the 6-month period before Day 0 (per available data)
2. Stable diet, including medical formula
3. Must be a man or a woman not of childbearing potential and agree to use adequate contraception throughout and for one year following study participation.
4. Adequate organ function
5. Negative antibody detection on type and screen and no evidence of clinical hemolysis

Exclusion Criteria

1. Known hypersensitivity to any component of study treatment
2. Prior treatment with Pegaliase
3. Start of sapropterin dihydrochloride within 3 weeks of study dosing
4. Use of an investigational agent within 28 days of study dosing
5. Concurrent participation in an interventional trial involving ongoing treatment, including placebo.
6. Infections requiring antimicrobial treatment within 7 days of study dosing
7. Chronic infections, such as HIV, hepatitis B, or untreated hepatitis C
8. Conditions that may alter survival of red blood cells, (e.g., autoimmune diseases, splenectomy, etc)
9. Pregnant or breastfeeding
Linking Tau PET to Medial Temporal Lobe Subregions With High Resolution MRI

The investigators will conduct a tau PET scan in cognitively normal older adults and patients with Mild Cognitive Impairment (MCI), enrolled in the National Alzheimer's Coordinating Center (NACC) study at the University of Pennsylvania's Penn Memory Center/Alzheimer's Disease Core Center (PMC/ADC).

This is a cross-sectional and longitudinal study using the radiotracer \[18F\]-PI-2620 to determine the relationship of tau pathology to both cross-sectional and longitudinal clinical and biomarker data of NACC cohort participants who are Cognitively Normal or MCI. All subjects will already be part of the longitudinal cohort study, known as the "NACC" cohort, of the PMC/ADC (protocol 068200). Participants will provide informed consent for this protocol before beginning any study procedures. After screening assessments, participants will undergo PET scan imaging with \[18F\]PI-2620. There will be one follow-up \[18F\]PI-2620 PET scan approximately 18 +/- 6 months after bas eline scan.

Eligibility Criteria:
Inclusion Criteria:

* Males and females ≥ 60 years of age.
* Part of the NACC longitudinal cohort (IRB# 068200) of the PMC/ADCC with consensus conference designation of cognitively normal or Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) Possible or Probable.
* NACC longitudinal visit completed or scheduled within 6 months before or after enrollment in this study.
* Women must be post-menopausal or surgically sterile.
* An amyloid PET scan, completed as a part of the NACC protocol (IRB# 825943), must be performed or scheduled within 12 months before or after the \[18F\]PI-2620 PET scan.
* A brain MRI, completed as a part of NACC protocol (IRB# 068200), must be performed or scheduled within 6 months before or after the \[18F\]PI-2620 PET scan. Scan should be of adequate research quality, including 3 Tesla and/or 7 Tesla high-resolution imaging of MTL structure.

Exclusion Criteria:

* Have any medical or psychiatric conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.
* Have evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with analysis of the PET scan.
* Inability to tolerate or contraindication to imaging procedures in the opinion of an investigator or treating physician.
* Have a history of significant or ongoing alcohol abuse or substance abuse or dependence based on medical record review or self-reported.

The inclusion / exclusion criteria will be ascertained through self-report in conjunction with any medical history available through the participant's medical or research records (EPIC or the ADC database)
Clinical and Radiological Results of Osteochondral Repair Using MaioRegen in Knee and Ankle Surgery

Osteochondral lesions in knee and ankle are injuries commonly seen in young patients. MaioRegen fleece is a cartilage substitute which can be used in circumscribed defects.

This prospective study follows patients treated with MaioRegen implants from pre-surgery until 24 months post-surgery.


Eligibility Criteria:
Inclusion Criteria:

* single osteochondral lesion in knee/ankle (2-4 sq cm)

Exclusion Criteria:

* multiple osteochondral lesions
* pre-existing injuries/arthropathies
Inverted T Trabeculectomy Primary Congenital Glaucoma

This study aims to evaluate the safety and efficacy of novel Inverted T trabeculectomy in Primary Congenital Glaucoma (PCG). It enrolled 50 eyes of 25 children with PCG. The mean age at the time of surgery was 12±11 months, and the mean presenting IOP was 40±4 mmHg. Patients with previous intra-ocular or conjunctival surgery, those who had significant ocular trauma, and patients with congenital glaucoma associated with ocular anomalies diseases were excluded from the study. All patients had Inverted T trabeculectomy under general anesthesia. The IOP in the operated eyes was followed up for 36 months.

This study included patients from the glaucoma clinic at Benha University Hospital between April 2015 and October 2017. All were diagnosed with PCG based on an intraocular pressure (IOP) measurement of 21 mmHg or more at birth or shortly after, up to the age of 12 months. Patients with previous intraocular or conjunctival surgery, those with significant ocular trauma, and those with congenital glaucoma associated with other ocular anomalies that would affect IOP were excluded from the study.

The procedure principles and potential complications were discussed with the children's parents or legal guardians, and they gave written informed consent before surgery. This study was approved by the Benha Faculty of Medicine's ethical committee (Approval number RC 9-1-2025) and conducted according to Helsinki's declaration.

All patients underwent complete ophthalmic examination under general anaesthesia before surgery. IOP was measured 5 minutes after injecting intravenous Ketamine 1mg/kg for induction of anaesthesia. We used a Perkins tonometer (Haag-Streit, UK) to measure the IOP before applying the eyelid speculum. Corneal clarity was assessed under a surgical microscope, the corneal diameter was recorded using a surgical caliber, and fundus examination was done by indirect ophthalmoscope. A surgical Swan Jacob gonioprism assessed the anterior chamber angle when the cornea was clear enough to achieve a good view.

All surgeries were performed under general anaesthesia by the same surgeon (AEH).

Eligibility Criteria:
Inclusion Criteria:

* PCG based on an intraocular pressure (IOP) measurement of 21 mmHg or more at birth or shortly after, up to the age of 12 months

Exclusion Criteria:

* Patients with previous intraocular or conjunctival surgery, those with significant ocular trauma, and those with congenital glaucoma associated with other ocular anomalies that would affect IOP were excluded from the study
Sun Protection and Tanning Awareness in Rural Schools

Drawing from prior school-based skin cancer prevention programs, we have adapted intervention materials to target rural high schoolers. Program components (including in-class education) will be co-implemented by the research team and participating school staff, with a focus on sustainability beyond the immediate study period. Interviews and surveys following initial implementation will evaluate both the effectiveness of the program.

The STARS study pilot tests a skin cancer prevention intervention adapted for use in rural schools. Participants will be recruited from approximately 14 districts in Utah. We have established collaborations with schools, districts, and the Utah State Board of Education (USBE) and they are committed to partnering with us on this project.

The research coordinator will contact district-level officials who will be asked to express their support of the study when facilitating the coordinator's contact with school principals and teachers (e.g., health teachers, science teachers). The research coordinator will also directly contact school principals and teachers to discuss participation in the study.

An intervention visit, lasting up to 90 minutes, will take place immediately following completion of a baseline survey. This intervention visit may be divided into 2 days, depending on the length of the class periods at the participating schools. During the intervention visit, students will receive general education on skin cancer and skin cancer prevention, complete a skin cancer risk self-assessment tool, and create a sun protection action plan for an outdoor activity.

One month later, participants will receive a brief (15-minute) post-intervention survey via email and/or text.

Eligibility Criteria:
Inclusion Criteria:

* Students are eligible if they are enrolled in a Utah high school (e.g. grades 9-12).

Exclusion Criteria:

* None